Clinical Trials Logo
  1. Home
  2. Acute Ischaemic Stroke
  3. NCT03463551

Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic — POST-IT  

Acute Ischaemic Stroke Clinical Trial

Official title:
Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic (POST-IT)

Clinical Trial Summary

This study evaluates the safety and tolerability of 3 dose levels of ABL-101 and supplemental oxygen in acute stroke patients.

Clinical Trial Description

Only a small proportion of patients are currently suitable for treatment with "clot busting" drugs after a stroke. Being able to visualise potentially rescuable brain tissue on scanning may allow more people to be treated. Currently available methods require extra time to acquire and are not therefore widely used. By carrying significant extra oxygen to the brain, the ABL-101 molecule may not only allow the visualisation of salvageable tissue, but also prevent progression of stroke damage in and have an additional direct benefit on tissue survival. Studies in animal models of stroke show smaller areas of stroke damage after ABL-101. There is therefore a rationale for testing this molecule in stroke patients, both as a diagnostic method, and also as a potential therapeutic agent. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03463551
Study type Interventional
Source NHS Greater Glasgow and Clyde
Contact Maureen Travers
Phone +44 1412321813
Email Maureen.Travers@ggc.scot.nhs.uk
Status Not yet recruiting
Phase Phase 2
Start date September 2018
Completion date March 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT02164357 - Efficacy and Security of an Endovascular Treatment as First Choice Procedure Compared With a Standard Intravenous Thrombolytic Therapy Treatment for Patients With Acute Ischemic Stroke Within 4.5 Hours After Onset N/A
Recruiting NCT01207336 - Combined tDCS+PNS After Acute Stroke Phase 2/Phase 3
Completed NCT03328403 - Endovascular Therapy in Acute Ischaemic Stroke Due to Large Vessel Occlusion N/A
Recruiting NCT06379464 - Screening of New Markers of Gut Microbiota in Stroke and Depression: a Cross-sectional Study
Completed NCT03971526 - Magnetic Resonance Post-contrast Vascular Hyperintensities at 3 T: a Sensitive Sign of Vascular Occlusion in Acute Ischaemic Stroke
Recruiting NCT03639922 - Imatinib in Acute Ischaemic Stroke Phase 3
Completed NCT03865225 - Effects of Heart Rate Variability Biofeedback in Patients With Acute Ischemic Stroke N/A
Completed NCT03541668 - Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST) Phase 3
Completed NCT03354429 - THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death Phase 3
Completed NCT01994720 - [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] Phase 3
Terminated NCT01745692 - Pragmatic Ischaemic Stroke Thrombectomy Evaluation N/A
Completed NCT03578822 - Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial Phase 3